An overviewof tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer

作者：Wang Zhijie; Fu Siqing^*

来源：Expert Opinion on Investigational Drugs, 2016, 25(1): 15-30.

DOI：10.1517/13543784.2016.1117071

• early drug development
• epithelial ovarian cancer
• objective response
• overall survival
• progression-free survival
• targeted therapy
• tyrosine kinase inhibitors

Introduction: Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy and the fifth most common cause of cancer-related deaths in women. Initial treatment with surgery and chemotherapy has improved survival significantly. However, the disease progresses or recurs in most patients. Thus, there is an urgent need to develop more effective treatment strategies.Areas covered: This article provides an overview of tyrosine kinase inhibitors (TKIs) for the treatment of EOC, which is based on English peer-reviewed articles on MEDLINE and related abstracts presented at major conferences. The authors highlight the data from the published clinical trials in EOC patients who were treated with TKIs or TKI-based regimens.Expert opinion: EOC is responsive to most chemotherapeutic drugs and/or biological agents and represents an ideal disease model for investigating novel anti-cancer agents. Numerous small-molecule TKIs targeting the VEGFR, PARP, PI3K-AKT-mTOR, MAPK, Src, PKC, Wee1 and HER1/2 signaling pathways are currently being tested in clinical trials. Research is needed for devising regimens combining TKIs with other agents in an optimal timing schedule and for identifying potential biomarkers predictive of response and survival.

• 出版日期2016-1-2
• 单位北京市肿瘤防治研究所; 北京大学